LathamTECH in Focus: Crypto’s Path to Engaging with the SEC
Latham & Watkins
LathamTECH in Focus: Crypto’s Path to Engaging with the SEC
2:16
LathamTECH in Focus: Will Dual Class Shares Fade Away?
Latham & Watkins
LathamTECH in Focus: Will Dual Class Shares Fade Away?
2:25
LathamTECH in Focus: Sustainability and Governance Considerations in Proxy Season
Latham & Watkins
LathamTECH in Focus: Sustainability and Governance Considerations in Proxy Season
2:12
UK FinReg Focus Areas in 2025: Sectoral Trends
Latham & Watkins
UK FinReg Focus Areas in 2025: Sectoral Trends
29:45
EU’s Digital Operational Resilience Act: What You Should Know and How to Stay Compliant
Latham & Watkins
EU’s Digital Operational Resilience Act: What You Should Know and How to Stay Compliant
19:34
Public M&A Day in Frankfurt
Latham & Watkins
Public M&A Day in Frankfurt
1:48
Drug Pricing: FDA in the Age of Executive Orders and DOGE
Latham & Watkins
Drug Pricing: FDA in the Age of Executive Orders and DOGE
22:14
Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
Latham & Watkins
Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
22:13
LathamTECH in Focus: Trade Secrets — Goldmine or Landmine?
Latham & Watkins
LathamTECH in Focus: Trade Secrets — Goldmine or Landmine?
2:09
LathamTECH in Focus: A Consumer Law Gamechanger
Latham & Watkins
LathamTECH in Focus: A Consumer Law Gamechanger
2:10
Michael Rubin at Latham and Deloitte’s US IPO Symposium at Nasdaq
Latham & Watkins
Michael Rubin at Latham and Deloitte’s US IPO Symposium at Nasdaq
0:50
UK FinReg Focus Areas in 2025: Retail Markets
Latham & Watkins
UK FinReg Focus Areas in 2025: Retail Markets
20:32
UK FinReg Focus Areas in 2025: Wholesale Markets
Latham & Watkins
UK FinReg Focus Areas in 2025: Wholesale Markets
23:23
What is LathamTECH?
Latham & Watkins
What is LathamTECH?
0:47
Word of the Day: UPREIT Book of Jargon® - Real Estate & REITs
Latham & Watkins
Word of the Day: UPREIT Book of Jargon® - Real Estate & REITs
1:05
How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech
Latham & Watkins
How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech
47:21
Keith Halverstam at Latham and Deloitte’s US IPO Symposium at Nasdaq
Latham & Watkins
Keith Halverstam at Latham and Deloitte’s US IPO Symposium at Nasdaq
0:27
Pro Bono Client Increases Access to Education
Latham & Watkins
Pro Bono Client Increases Access to Education
2:48
Michael Benjamin at Latham and Deloitte’s US IPO Symposium at Nasdaq
Latham & Watkins
Michael Benjamin at Latham and Deloitte’s US IPO Symposium at Nasdaq
0:54
Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?
Latham & Watkins
Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?
33:12
Ian Schuman at Latham and Deloitte’s US IPO Symposium at Nasdaq
Latham & Watkins
Ian Schuman at Latham and Deloitte’s US IPO Symposium at Nasdaq
0:47
Latham and Deloitte’s US IPO Symposium at Nasdaq
Latham & Watkins
Latham and Deloitte’s US IPO Symposium at Nasdaq
1:54
Paris LathamAlumni Event
Latham & Watkins
Paris LathamAlumni Event
1:08
Drug Pricing: What’s in the New CMS Medicaid Final Rule?
Latham & Watkins
Drug Pricing: What’s in the New CMS Medicaid Final Rule?
28:38
Welcome to AI Academy
Latham & Watkins
Welcome to AI Academy
3:31
Drug Pricing: How The Demise of Chevron Deference and Litigation May Impact Pharmaceutical Industry
Latham & Watkins
Drug Pricing: How The Demise of Chevron Deference and Litigation May Impact Pharmaceutical Industry
21:50
Latham in Focus: Energy & Infrastructure — What’s New in Energy Debt Finance?
Latham & Watkins
Latham in Focus: Energy & Infrastructure — What’s New in Energy Debt Finance?
1:20
Drug Pricing: Takeaways From the Chicago Medicaid Drug Rebate Program Summit
Latham & Watkins
Drug Pricing: Takeaways From the Chicago Medicaid Drug Rebate Program Summit
18:25
Latham in Focus: Emerging Companies & Growth — Growth vs. Traditional Financings
Latham & Watkins
Latham in Focus: Emerging Companies & Growth — Growth vs. Traditional Financings
1:50
2025 London Vacation and First Year Schemes
Latham & Watkins
2025 London Vacation and First Year Schemes
1:37
Latham in Focus: Energy & Infrastructure — Utilizing Incremental Capacity in Reserve Based Loans
Latham & Watkins
Latham in Focus: Energy & Infrastructure — Utilizing Incremental Capacity in Reserve Based Loans
1:35
Pro Bono Client Helps Transform Chicago Neighborhood
Latham & Watkins
Pro Bono Client Helps Transform Chicago Neighborhood
2:45
UK FinReg Focus Areas in 2024: ESG
Latham & Watkins
UK FinReg Focus Areas in 2024: ESG
17:14
Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
Latham & Watkins
Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
16:04
UK FinReg Focus Areas in 2024: Enforcement Against Individuals
Latham & Watkins
UK FinReg Focus Areas in 2024: Enforcement Against Individuals
8:23
UK FinReg Focus Areas in 2024: Regulatory Divergence
Latham & Watkins
UK FinReg Focus Areas in 2024: Regulatory Divergence
17:50
UK FinReg Focus Areas in 2024: Enforcement Against Firms
Latham & Watkins
UK FinReg Focus Areas in 2024: Enforcement Against Firms
13:25
UK FinReg Focus Areas in 2024: Conduct and Culture
Latham & Watkins
UK FinReg Focus Areas in 2024: Conduct and Culture
13:20
Pro Bono: Shabir Kabiri’s Remarkable Journey from Afghanistan to Asylum in the US
Latham & Watkins
Pro Bono: Shabir Kabiri’s Remarkable Journey from Afghanistan to Asylum in the US
34:24
Episode 84 – Pro Bono: Shabir Kabiri’s Remarkable Journey from Afghanistan to Asylum in the US
Latham & Watkins
Episode 84 – Pro Bono: Shabir Kabiri’s Remarkable Journey from Afghanistan to Asylum in the US
34:24
Drug Pricing: How Are Payers Responding to the IRA?
Latham & Watkins
Drug Pricing: How Are Payers Responding to the IRA?
29:18
Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?
Latham & Watkins
Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?
29:18
The LathamAlumni Community
Latham & Watkins
The LathamAlumni Community
1:49
Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference
Latham & Watkins
Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference
17:31
Drug Pricing: A Look Behind the Curtain of New ASP Reporting Website & Other Data Collection Portals
Latham & Watkins
Drug Pricing: A Look Behind the Curtain of New ASP Reporting Website & Other Data Collection Portals
23:38
Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?
Latham & Watkins
Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?
26:13
Latham's Diversity Leadership Academies
Latham & Watkins
Latham's Diversity Leadership Academies
2:02
My London Trainee Experience
Latham & Watkins
My London Trainee Experience
1:45
My Latham Summer 2024
Latham & Watkins
My Latham Summer 2024
3:03
Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference
Latham & Watkins
Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference
17:33
Episode 81 – Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other D...
Latham & Watkins
Episode 81 – Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other D...
23:37
Episode 80 – Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?
Latham & Watkins
Episode 80 – Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?
26:15
2023 Robert M. Dell Prize: The Jason Sissel Matter
Latham & Watkins
2023 Robert M. Dell Prize: The Jason Sissel Matter
5:35
UK FinReg Focus Areas in 2024: Artificial Intelligence
Latham & Watkins
UK FinReg Focus Areas in 2024: Artificial Intelligence
13:52
Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
Latham & Watkins
Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
16:04
2023 Pro Bono Annual Review
Latham & Watkins
2023 Pro Bono Annual Review
0:58
Latham in Focus: Energy & Infrastructure — Transfer Bridge Loans
Latham & Watkins
Latham in Focus: Energy & Infrastructure — Transfer Bridge Loans
1:20
Latham in Focus: Energy & Infrastructure — Selling Energy Tax Credits
Latham & Watkins
Latham in Focus: Energy & Infrastructure — Selling Energy Tax Credits
2:08
Episode 78 – UK FinReg Focus Areas in 2024: ESG
Latham & Watkins
Episode 78 – UK FinReg Focus Areas in 2024: ESG
17:14
Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals
Latham & Watkins
Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals
8:23
Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence
Latham & Watkins
Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence
17:50
Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms
Latham & Watkins
Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms
13:25
Latham In Focus: Energy & Infrastructure — Redeveloping US Coal-Fired Power Plants
Latham & Watkins
Latham In Focus: Energy & Infrastructure — Redeveloping US Coal-Fired Power Plants
2:06
Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture
Latham & Watkins
Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture
13:20
UK FinReg Focus Areas in 2024: The Edinburgh Reforms
Latham & Watkins
UK FinReg Focus Areas in 2024: The Edinburgh Reforms
10:16
Drug Pricing: A Look Ahead at Trends for 2024
Latham & Watkins
Drug Pricing: A Look Ahead at Trends for 2024
11:46
UK FinReg Focus Areas in 2024: Investment Research
Latham & Watkins
UK FinReg Focus Areas in 2024: Investment Research
17:12
UK FinReg Focus Areas in 2024 Retail Markets — Direction of Travel
Latham & Watkins
UK FinReg Focus Areas in 2024 Retail Markets — Direction of Travel
13:47
PE Views: The Most Pressing Cybersecurity Considerations for Private Equity
Latham & Watkins
PE Views: The Most Pressing Cybersecurity Considerations for Private Equity
33:53
Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?
Latham & Watkins
Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?
13:38
UK FinReg Focus Areas in 2024: Primary Markets Reform
Latham & Watkins
UK FinReg Focus Areas in 2024: Primary Markets Reform
13:52
Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence
Latham & Watkins
Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence
13:55
Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms
Latham & Watkins
Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms
10:19
Episode 71 – Drug Pricing: A Look Ahead at Trends for 2024
Latham & Watkins
Episode 71 – Drug Pricing: A Look Ahead at Trends for 2024
11:48
Episode 70 – UK FinReg Focus Areas in 2024: Investment Research
Latham & Watkins
Episode 70 – UK FinReg Focus Areas in 2024: Investment Research
17:15
Episode 69 – UK FinReg Focus Areas in 2024: Retail Markets – Direction of Travel
Latham & Watkins
Episode 69 – UK FinReg Focus Areas in 2024: Retail Markets – Direction of Travel
13:50
Episode 68 – Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?
Latham & Watkins
Episode 68 – Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?
13:39
Episode 67 – PE Views: The Most Pressing Cybersecurity Considerations For Private Equity
Latham & Watkins
Episode 67 – PE Views: The Most Pressing Cybersecurity Considerations For Private Equity
33:59
Episode 66 – UK FinReg Focus Areas in 2024: Primary Markets Reform
Latham & Watkins
Episode 66 – UK FinReg Focus Areas in 2024: Primary Markets Reform
13:55
Word of the Day: Reasonable Anticipation of Litigation Book of Jargon® - eDiscovery
Latham & Watkins
Word of the Day: Reasonable Anticipation of Litigation Book of Jargon® - eDiscovery
0:49
PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ESG Scrutiny?
Latham & Watkins
PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ESG Scrutiny?
9:47
Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Litigation Risks?
Latham & Watkins
Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Litigation Risks?
25:50
Episode 65 – PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ES...
Latham & Watkins
Episode 65 – PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ES...
9:51
Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?
Latham & Watkins
Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?
26:21
M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?
Latham & Watkins
M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?
13:57
Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program
Latham & Watkins
Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program
12:00
Episode 64 – Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Li...
Latham & Watkins
Episode 64 – Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Li...
25:52
Episode 63 – M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?
Latham & Watkins
Episode 63 – M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?
13:57
Episode 62 – Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?
Latham & Watkins
Episode 62 – Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?
26:26
Episode 61 – Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Complian...
Latham & Watkins
Episode 61 – Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Complian...
12:45
PE Views: Is the CMA’s Focus on Roll-Up Transactions Here to Stay?
Latham & Watkins
PE Views: Is the CMA’s Focus on Roll-Up Transactions Here to Stay?
10:28
Episode 60 – PE Views: Is the CMA’s Focus on Roll-Up Transactions Here to Stay?
Latham & Watkins
Episode 60 – PE Views: Is the CMA’s Focus on Roll-Up Transactions Here to Stay?
10:28
SCOTUS Update: Perez v. Sturgis Secures a Supreme Court Win for Disability Rights
Latham & Watkins
SCOTUS Update: Perez v. Sturgis Secures a Supreme Court Win for Disability Rights
37:08
Episode 59 – SCOTUS Update: Perez v. Sturgis Secures a Supreme Court Win for Disability Rights
Latham & Watkins
Episode 59 – SCOTUS Update: Perez v. Sturgis Secures a Supreme Court Win for Disability Rights
37:08
FDI Developments: M&A Security Screening in Europe's Fragmented FDI Landscape
Latham & Watkins
FDI Developments: M&A Security Screening in Europe's Fragmented FDI Landscape
19:28
Word of the Day: Punitive Dilution Book of Jargon® — Real Estate & REITs
Latham & Watkins
Word of the Day: Punitive Dilution Book of Jargon® — Real Estate & REITs
1:35
Austin Public Company Summit 2023
Latham & Watkins
Austin Public Company Summit 2023
1:52
Episode 58 – FDI Developments: M&A Security Screening in Europe's Fragmented FDI Landscape
Latham & Watkins
Episode 58 – FDI Developments: M&A Security Screening in Europe's Fragmented FDI Landscape
19:36
Drug Pricing: What Trends Emerged from the 2023 Medicaid Drug Rebate Program Summit?
Latham & Watkins
Drug Pricing: What Trends Emerged from the 2023 Medicaid Drug Rebate Program Summit?
12:07
Episode 57 – Drug Pricing: What Trends Emerged from the 2023 Medicaid Drug Rebate Program Summit?
Latham & Watkins
Episode 57 – Drug Pricing: What Trends Emerged from the 2023 Medicaid Drug Rebate Program Summit?
12:12